Aro Biotherapeutics identifies how its tech can fight a genetic disorder
A Philadelphia biotechnology company founded four years ago by two former Johnson& Johnson executives has identified a lead target for its silencing-RNA technology.
Aro Biotherapeutics has generated positive preclinical study results for a potential treatment for Pompe disease, a rare inherited disorder caused by the buildup of glycogen, a complex sugar, in the body's cells.
Pompe disease, which can begin a few months after birth or later in life, afflicts an estimated one in 40,000 people in…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news